June 25, 2009 – Smiths Medical today launched its new BCI SPECTRO2 Pulse Oximetry Portfolio, designed for a variety of patient care settings.
The new line includes three models: the SPECTRO2l10, SPECTRO2l20 and SPECTRO2l30 Pulse Oximeters. The portfolio is built on a foundation of proprietary BCI technology and delivers accurate, trustworthy readings across a full range of patient care settings, even during motion or low perfusion conditions.
The SPECTRO2l10 Pulse Oximeter is designed for use in primary care environments. The SPECTRO2l20 Pulse Oximeter features patented BCI serial autocorrelation technology, which allows it to deliver reliable spot-check results in some of the most challenging clinical settings, including those with the presence of low perfusion or motion. The SPECTRO2l30 Pulse Oximeter has the same features as the other two models, plus multiple operating modes with audible and visual alarms and the availability of a nurse call system that alerts healthcare providers for potential clinical intervention to ensure patient safety.
The portfolio’s array of accessories makes it possible to customize a solution to suit each environment’s specific needs. Features of the SPECTRO2 Pulse Oximetry Portfolio include: on-board cradle to store and protect the sensor; BCI spot-check finger sensor; pulse amplitude Index (PI) bar-graph indicator to help clinicians choose a good test site; memory storage for up to 99 patients; large, bright LED display; and a three-year warranty.
For more information: www.smiths-medical.com